NCT00569192View on ClinicalTrials.gov

A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children

PHASE3CompletedINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

January 31, 2009

Conditions
Asthma
Interventions
DRUG

0.135mg MAP0010

0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks

DRUG

0.25mg MAP0010

0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks

DRUG

Placebo

Placebo delivered by nebulization twice daily for 12 weeks

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
collaborator

MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

INDUSTRY

lead

Allergan

INDUSTRY